JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264034

Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Monoclonal Amyloid-beta precursor protein antibody. Suitable for WB, I-ELISA, Dot and reacts with Human, Synthetic peptide samples.

View Alternative Names

A4, AD1, APP, Amyloid-beta precursor protein, ABPP, APPI, Alzheimer disease amyloid A4 protein homolog, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta (A4) precursor protein, Amyloid-beta A4 protein, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, CVAP, PN-II

3 Images
Indirect ELISA - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034)
  • I-ELISA

Supplier Data

Indirect ELISA - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034)

Indirect ELISA antibody dose-response curve using ab264034 with antigen at 1000 ng/ml

Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034)
  • WB

Supplier Data

Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034)

Blocking and diluting buffer and concentration was 5% NFDM/TBST.

Lanes 1 - 2:

Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab264034) at 1/1000 dilution

Lanes 1 - 2:

Western blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (ab290645) at 1/1000 dilution

Lane 1:

beta Amyloid pE3-42 (aa674-713) peptide 100ng

Lane 2:

beta Amyloid 1-42 (aa672-713) peptide 100ng

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/1000000 dilution

false

Exposure time: 3s

Dot Blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034)
  • Dot

Supplier Data

Dot Blot - Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] (AB264034)

Dot blot analysis of pyroglutamate beta amyloid using ab264034 at 1/2000 dilution, followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/100,000 dilution.

Blocking and diluting buffer and concentration was 5% NFDM/TBST.

Lane 1 : beta Amyloid pE3-42 (aa674-713) peptide

Lane 2 : beta Amyloid 1-42 (aa672-713) peptide

Exposure time : 3 minutes.

  • Carrier free

    Anti-Pyroglutamate beta Amyloid antibody [IBR-10-2-3] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

IBR-10-2-3

Isotype

IgG1

Carrier free

No

Reacts with

Human

Applications

WB, I-ELISA, Dot

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IELISA" : {"fullname" : "Indirect ELISA", "shortname":"I-ELISA"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IELISA-species-checked": "testedAndGuaranteed", "IELISA-species-dilution-info": "0.0625 µg/mL", "IELISA-species-notes": "<p></p>", "Dot-species-checked": "guaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Synthetic peptide": { "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "IELISA-species-checked": "notRecommended", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "1/2000", "Dot-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Pyroglutamate beta amyloid also known by its abbreviation pGlu-Aβ is a modified form of beta amyloid that plays a significant role in the pathology of Alzheimer's disease. This peptide is approximately 40-42 amino acids in length contributing to its molecular mass range of 4 to 5 kDa. Pyroglutamate beta amyloid is generated through a post-translational modification where glutamate residues on beta amyloid undergo cyclization. This modification imparts stability and resistance to degradation causing it to accumulate in the brain. Researchers find pyroglutamate beta amyloid mainly in the neurons and plaques of the brains of Alzheimer’s patients.
Biological function summary

Pyroglutamate beta amyloid affects neuronal function by increasing the aggregation propensity of beta amyloid. It enhances the toxic effects on synapses and neurons disrupting communication and leading to synaptic dysfunction. Pyroglutamate-modified amyloid beta is a component of the amyloid plaque complex which includes other amyloid peptides and metal ions. The presence of pGlu-Aβ in these plaques enhances their stability and neurotoxicity accelerating neuronal degradation and loss of cognitive functions.

Pathways

Modified pyroglutamate beta amyloid involves itself in amyloidogenic pathways that include processes such as the beta-secretase and gamma-secretase pathways. These pathways lead to production and modification of amyloid beta peptide initiating plaque formation in the brain. The interaction of pyroglutamate beta amyloid with tau protein is significant as the aggregation of these proteins advances neurodegeneration. Tau proteins become hyperphosphorylated in response disrupting cellular transport and further promoting Alzheimer's disease progression.

Pyroglutamate beta amyloid connects closely with Alzheimer's disease where its modified form accelerates plaque formation and neurodegeneration. Researchers also study its role in frontotemporal dementia another neurodegenerative disorder characterized by tau protein dysfunction. The aggregation of pyroglutamate beta amyloid interacts with other forms of amyloid beta as well as tau contributing to the pathological hallmarks of these disorders.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis (PubMed : 25122912). Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1 (By similarity). By acting as a kinesin I membrane receptor, plays a role in axonal anterograde transport of cargo towards synapses in axons (PubMed : 17062754, PubMed : 23011729). Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.. Amyloid-beta peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Amyloid-beta protein 42 is a more effective reductant than amyloid-beta protein 40. Amyloid-beta peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. APP42-beta may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts.. Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.. The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.
See full target information APP

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com